Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid

European Urology

Volumn 59, Issue 4, 2011, Pages 604-612

  Jung, Klaus ^a,b   Miller, Kurt ^a   Wirth, Manfred ^c   Albrecht, Michael ^d   Lein, Michael ^a,b,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e University Teaching Hospital   (Germany)

Author keywords

Bone markers; Bone metastases; Overall survival; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RELIABILITY; RISK ASSESSMENT;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; CLINICAL TRIALS AS TOPIC; COLLAGEN TYPE I; DIPHOSPHONATES; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MULTICENTER STUDIES AS TOPIC; PEPTIDE FRAGMENTS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK FACTORS;

EID: 79952280947     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.12.006     Document Type: Article

References (27)

1. J.E. Brown, R.J. Cook, and P. Major Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 2005 59 69
2. R.J. Cook, R. Coleman, and J. Brown Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer Clin Cancer Res 12 2006 3361 3367
3. M.R. Smith, R.J. Cook, and R. Coleman Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer Urology 70 2007 315 319 (Pubitemid 47362256)
4. M.J. Seibel The use of molecular markers of bone turnover in the management of patients with metastatic bone disease Clin Endocrinol (Oxf) 68 2008 839 849 (Pubitemid 351703933)
5. M. Lein, M. Wirth, and K. Miller Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression Eur Urol 52 2007 1381 1387 (Pubitemid 47445973)
6. K. Jung, M. Lein, and C. Stephan Comparison of ten serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications Int J Cancer 111 2004 783 791 (Pubitemid 39062904)
7. R.E. Coleman, P. Major, and A. Lipton Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 2005 4925 4935 (Pubitemid 46223998)
8. M. Lein, K. Miller, and M. Wirth Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid Prostate 69 2009 624 632
9. N. Kamiya, H. Suzuki, and M. Yano Implications of serum bone turnover markers in prostate cancer patients with bone metastasis Urology 75 2010 1446 1451
10. S. Rajpar, C. Massard, and A. Laplanche Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer Ann Oncol 21 2010 1864 1869
11. Schröder B. Evaluating the predictive performance of species distribution models. Universität Potsdam Web site. http://brandenburg. geoecology.uni-potsdam.de/users/schroeder/download.html. Accessed September 21, 2010.
12. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387 (Pubitemid 26072233)
13. G. Lughezzani, A. Briganti, and P.I. Karakiewicz Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature Eur Urol 58 2010 687 700
14. O. Smaletz, H.I. Scher, and E.J. Small Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 2002 3972 3982
15. A.J. Armstrong, E.S. Garrett-Mayer, Y.C. Yang, R. de Wit, I.F. Tannock, and M. Eisenberger A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403 (Pubitemid 350075029)
16. S. Halabi, N.J. Vogelzang, and A.B. Kornblith Pain predicts overall survival in men with metastatic castration-refractory prostate cancer J Clin Oncol 26 2008 2544 2549
17. A.J. Armstrong, E. Garrett-Mayer, R. de Wit, I. Tannock, and M. Eisenberger Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 16 2010 203 211
18. R. Nayyar, N. Sharma, and N.P. Gupta Prognostic factors affecting progression and survival in metastatic prostate cancer Urol Int 84 2010 159 163
19. J. Shamash, J. Stebbing, and C. Sweeney A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer Cancer 116 2010 3595 3602
20. H. Maeda, M. Koizumi, K. Yoshimura, T. Yamauchi, T. Kawai, and E. Ogata Correlation between bone metabolic markers and bone scan in prostatic cancer J Urol 157 1997 539 543 (Pubitemid 27026833)
21. R.C. Percival, G.H. Urwin, and S. Harris Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption Eur J Surg Oncol 13 1987 41 49 (Pubitemid 17040425)
22. A. Ramankulov, M. Lein, G. Kristiansen, S.A. Loening, and K. Jung Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer Prostate 67 2007 330 340
23. N. Koopmans, I.J. de Jong, A.J. Breeuwsma, and E. van der Veer Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach J Urol 178 2007 849 853 (Pubitemid 47211070)
24. P.N. Lara Jr., W.M. Stadler, and J. Longmate A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin Cancer Res 12 2006 1556 1563
25. A. Zafeirakis, G. Papatheodorou, A. Arhontakis, A. Gouliamos, L. Vlahos, and G.S. Limouris Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases Eur J Nucl Med Mol Imaging 37 2010 103 113
26. H.W. Woitge, M. Pecherstorfer, and Y. Li Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices J Bone Miner Res 14 1999 792 801 (Pubitemid 29210606)
27. F. Saad, and C.C. Schulman Role of bisphosphonates in prostate cancer Eur Urol 45 2004 26 34 (Pubitemid 37548989)